Dilution profile // every instrument, one screen, from SEC filings

MIRA PHARMACEUTICALS, INC. (MIRA)

CIK 1904286 · all EDGAR filings →

Overall dilution risk
HIGHworst of 3 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGHS-3 on file 2024-08-12
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
NOT COMPUTEDno warrant count tagged in XBRL
= warrant shares outstanding divided by current shares outstanding
absence of a tag is not proof of absence of warrants
Historical dilution
HIGH+184% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
MEDIUM~20.9 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2023-09-152026-08-10

Latest: 42.0M shares as of Aug 10, 2026 (10-Q).

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

Balance-sheet fair value of warrants: $1.8M as of Dec 31, 2024.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 12, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Registrations and offerings

S-3Aug 12, 2024no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-1Dec 18, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 2 executed · 0 registered.

EXECUTEDDec 5, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDSep 30, 2025Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDMay 21, 2025Unregistered share sale disclosed (8-K item 3.02)8-K
EXECUTEDApr 16, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EXECUTEDSep 27, 2024Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5
EFFECTIVEAug 16, 2024SEC declared a registration effective — selling can beginEFFECT
REGISTEREDAug 12, 2024S-3 registration — capacity to sell shares, not a sale yetS-3
EFFECTIVEDec 27, 2023SEC declared a registration effective — selling can beginEFFECT
REGISTEREDDec 18, 2023S-1 registration — capacity to sell shares, not a sale yetS-1
EXECUTEDNov 20, 2023Unregistered share sale disclosed (8-K item 3.02)8-K
UPDATENov 14, 2023Prospectus update — often a resale registration, not necessarily new capital424B3
UPDATESep 18, 2023Prospectus update — often a resale registration, not necessarily new capital424B3

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full MIRA workspace